What happened?
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ: JAZZ) jumped 8.4% in the afternoon session after the company reported record revenue in its third-quarter 2026 financial results and increased its full-year 2026 total revenue outlook.
According to a company press release, Jazz Pharmaceuticals reported third-quarter 2026 revenue of $1.24 billion, an increase of 10.4% year on year. The release also said the company lifted its full-year 2026 revenue guidance to $4.81 billion at the midpoint from $4.68 billion. Both the quarterly revenue and the updated guidance came in above Wall Street analysts' estimates. Adjusted earnings per share of negative $3.88 was below analysts' expectations of negative $2.38.
Is now the time to buy Jazz Pharmaceuticals? Access our full analysis report here, it’s free.
What is the market telling us
Jazz Pharmaceuticals’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 12 months ago when the stock gained 18.3% on the news that the company announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for its cancer drug, Ziihera. The study tested Ziihera as a first-line treatment for patients with a type of advanced or metastatic gastroesophageal cancer. The trial found that Ziihera, when used with chemotherapy, led to statistically significant and clinically meaningful improvements in progression-free survival compared to the current standard treatment. This means the drug helped patients live longer without their cancer getting worse.
Furthermore, when Ziihera was combined with chemotherapy and the checkpoint inhibitor tislelizumab, it also showed a significant improvement in overall survival rates. These strong results suggested that Ziihera-based treatments could become a new standard of care for this form of cancer.
Jazz Pharmaceuticals is up 33.6% since the beginning of the year, but at $231.30 per share, it is still trading 11.6% below its 52-week high of $261.62 from August 2026. Investors who bought $1,000 worth of Jazz Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $1,689.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
